ASCO 2022 | An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HL
Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, provides an overview of the updated analysis of the Phase III ECHELON-1 trial (NCT01712490) investigating first-line brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (AVBD) to improve overall survival (OS) in patients with stage III/IV classical Hodgkin lymphoma. The primary endpoint was progression-free survival (PFS) and a key secondary endpoint was OS. The key secondary endpoint of OS was met with A+AVD corresponding to a 41% decrease in risk of death. Manageable side effects were reported for A+AVD, consistent with prior reports. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
